每经AI快讯，有投资者在投资者互动平台提问：同和药业的股价长期低迷，远远的跑输板块，狠狠的 伤害了广大投资人的心. 1.请问公司计划如何提振股价和广大股民的投资信心？ 2.能否介绍一下公司的 二厂区二期工程进度和生产计划？公司能否尽快提高一厂区和二厂区的产能利用率，大幅度扩广以提高 业绩。 3.公司能否收购和参股一些创新药公司以提振股价和广大股民的信心？ 同和药业（300636.SZ）8月15日在投资者互动平台表示， 1、公司上市以来聚焦主业，稳健经营，管理 层勤勉尽责，降本增效，持续研发，拓展业务，扩大营收，努力提升公司盈利水平，连续多年保持营业 收入与净利润持续增长，每年进行现金分红回馈投资者；公司上市以来高度重视市值管理工作，通过多 种形式与投资者开展互动，积极与广大投资者进行沟通和交流，主动向资本市场推广传播公司投资价 值。 2、公司二厂区二期工程已完成全部土建工程，其中2个生产车间将在今年下半年完成设备安装调 试并开始试生产，这2个车间可在2026年释放产能；质检研发大楼也将于今年下半年投入使用，将为进 一步提升公司的研发能力创造良好条件。 3、目前，创新药是资本市场的"热点"，但公司如果为了"博 ...

公司回答表示：感谢您对公司的关注！1、公司上市以来聚焦主业，稳健经营，管理层勤勉尽责，降本 增效，持续研发，拓展业务，扩大营收，努力提升公司盈利水平，连续多年保持营业收入与净利润持续 增长，每年进行现金分红回馈投资者；公司上市以来高度重视市值管理工作，通过多种形式与投资者开 展互动，积极与广大投资者进行沟通和交流，主动向资本市场推广传播公司投资价值。2、公司二厂区 二期工程已完成全部土建工程，其中2个生产车间将在今年下半年完成设备安装调试并开始试生产，这2 个车间可在2026年释放产能；质检研发大楼也将于今年下半年投入使用，将为进一步提升公司的研发能 力创造良好条件。3、目前，创新药是资本市场的"热点"，但公司如果为了"博眼球"和"蹭热点"，不从 公司实际出发，盲目收购和参股一些创新药公司，最后很大可能会成为公司的拖累。谢谢！ 金融界8月15日消息，有投资者在互动平台向同和药业提问：同和药业的股价长期低迷，远远的跑输板 块，狠狠的伤害了广大投资人的心. 1.请问公司计划如何提振股价和广大股民的投资信心？ 2.能否介绍 一下公司的二厂区二期工程进度和生产计划？公司能否尽快提高一厂区和二厂区的产能利用率，大幅度 ...

证券日报网讯 8月14日晚间，同和药业发布公告称，公司于近日收到江西省药品监督管理局的"江西省 药品监督管理局药品GMP符合性检查结果告知书（赣药品GMP（2025）第A0062号）"，获悉经现场检 查和综合评定，公司本次检查原料药美阿沙坦钾符合药品GMP。 （文章来源：证券日报） ...

北京商报讯（记者 王寅浩 实习记者 宋雨盈）8月14日，同和药业发布公告称，公司近日收到江西省药 品监督管理局药品GMP符合性检查结果告知书，此次检查的原料药美阿沙坦钾符合药品GMP。公告显 示，美阿沙坦钾适用于治疗成人原发性高血压。 ...

Group 1 - The company, Tonghe Pharmaceutical, has received a compliance inspection result from the Jiangxi Provincial Drug Administration regarding the GMP (Good Manufacturing Practice) for its raw material drug, Amlodipine Potassium [1] - The inspection confirmed that Amlodipine Potassium meets the GMP standards, which is essential for the treatment of adult primary hypertension [1]

每经AI快讯，8月14日，同和药业（300636）(300636.SZ)公告称，公司于近日收到江西省药品监督管理 局的药品GMP符合性检查结果告知书，获悉公司本次检查的原料药美阿沙坦钾符合药品GMP。此次检 查有利于公司拓展产品在国内市场的销售，形成国内国外市场同步销售的良好格局。但受市场环境等因 素影响，具体销售情况存在一定不确定性。公司将按照相关法律法规的要求对后续进展情况履行信息披 露义务。 ...

Core Viewpoint - The company has successfully passed the GMP compliance inspection for its raw material drug, Azilsartan Potassium, which is expected to enhance its sales in the domestic market and establish a synchronized sales pattern in both domestic and international markets [1] Group 1 - The drug Azilsartan Potassium is indicated for the treatment of primary hypertension in adults [1] - The successful GMP compliance is a significant milestone for the company, facilitating market expansion [1]

证券代码：300636 证券简称：同和药业 公告编号：2025-041 江西同和药业股份有限公司 | 企业名称 | 江西同和药业股份有限公司 | | --- | --- | | 生产地址 | 江西奉新高新技术产业园区天工大道888号 | | 检查范围 | 原料药（美阿沙坦钾） | | 检查日期 | 2025年5月17-19日 | | 检查结论 | 此次检查原料药（美阿沙坦钾）符合药品GMP | 美阿沙坦钾适用于治疗成人原发性高血压。 公司原料药美阿沙坦钾通过药品GMP符合性检查，有利于公司拓 展产品在国内市场的销售，形成国内国外市场同步销售的良好格局。 受市场环境等因素影响，上述原料药品种的具体销售情况存在一 定的不确定性，公司将按照相关法律法规的要求对后续进展情况履行 信息披露义务。敬请广大投资者理性投资，注意投资风险。 特此公告。 江西同和药业股份有限公司董事会 关于公司通过药品 GMP 符合性检查的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 江西同和药业股份有限公司（以下简称"公司")于近日收到江 西省药品监督管理局的"江西省药品监督管理局药品 ...

Core Viewpoint - Tonghe Pharmaceutical's investment in Hangzhou Boya Biopharmaceutical Co., Ltd. focuses on the development and production of long-acting complex formulations, but it is not classified as an innovative drug company [1] Company Information - Hangzhou Boya was established in 2023 and is based in Hangzhou, specializing in long-acting complex formulations [1] - The core team of Hangzhou Boya is led by Dr. Xia Jinqiang, who has over 30 years of experience in drug development and has held senior positions in major pharmaceutical companies [1] - Dr. Xia's credentials include a postdoctoral fellowship at Cornell University and a Ph.D. from Texas A&M University, along with a master's degree in analytical chemistry from the Dalian Institute of Chemical Physics [1] Research Focus - Hangzhou Boya's research is concentrated on complex dosage forms such as microsphere injectables, oral dissolving films, and biopharmaceuticals [1]

Group 1 - Weihai Guangtai reported a net profit of 83.32 million yuan for the first half of 2025, a year-on-year decrease of 22.41%, while total revenue reached 1.425 billion yuan, an increase of 10.91% [1] - Haowei Group expects a net profit increase of 39.43% to 49.67% for the first half of 2025, estimating a profit range of 1.906 billion to 2.046 billion yuan [1] - Tengda Construction won a bid for a project worth 118 million yuan, with a construction period of 500 calendar days [1] Group 2 - Shanda Power plans to use up to 520 million yuan of idle raised funds for cash management, investing in safe and liquid products with a term not exceeding 12 months [3] - Rundu Co., Ltd. received approval for the listing application of its chemical raw material drug, which is suitable for surgical treatment in adults and children over one month old [4] - Zhongyuan Qihua's subsidiary's clinical trial application for a drug aimed at treating pulmonary fibrosis has been accepted [4] Group 3 - Shanghai Xiba plans to establish a joint venture with Yuyuan Rare Earth, focusing on advanced materials for lithium-ion solid-state batteries, with a registered capital of 200 million yuan [6] - Aorite's senior management plans to reduce their holdings by up to 62,500 shares, accounting for 0.02% of the company's total equity [7] - Yipin Hong's subsidiary's clinical trial application for a new oral drug for endometriosis has been accepted [8] Group 4 - Haya Pharmaceutical plans to lease idle assets covering 22,671.39 square meters for a period of 10 years [9] - Southern Precision Engineering applied for a credit limit of 50 million yuan from a bank for operational purposes [11] - Jindawei's subsidiary established a joint venture with a registered capital of 5 million yuan, focusing on the sale of food additives and health products [12] Group 5 - Gaode Infrared signed a product order contract worth 307 million yuan, expected to account for 11.46% of the company's audited revenue for 2024 [13] - Xichang Electric will implement a low valley electricity price policy starting September 1, 2025, which is expected to reduce net profit by approximately 5.55 million yuan [14] - Huyou Pharmaceutical's first subject has been dosed in a Phase I clinical trial for a drug targeting advanced solid tumors [16] Group 6 - Chuanheng Co., Ltd. received a patent for a dust removal system in mining operations [17] - Spring Wind Power's application for issuing convertible bonds has been accepted by the Shanghai Stock Exchange [18] - Liuyao Group plans to repurchase shares worth between 100 million and 200 million yuan [19] Group 7 - Baiyun Electric has obtained a commitment letter for a stock repurchase loan of up to 18 million yuan [20] - Tonghe Pharmaceutical received a patent for a method of preparing an intermediate for a migraine treatment drug [21] - Tainkang's subsidiary's Phase II clinical trial for a drug for vitiligo has shown significant efficacy and safety [23] Group 8 - Yuhua Tian's secretary and deputy general manager resigned for personal reasons [24] - Heizhima's controlling shareholder is planning a change in control, leading to a temporary suspension of stock trading [25] - Keda Li's subsidiary completed a capital increase, raising its registered capital to 700 million yuan [26] Group 9 - Fangda Special Steel's shareholder plans to reduce holdings by up to 1% of the company's shares [28] - ST Pava's director is under investigation for alleged embezzlement, but the company's operations remain normal [29] - Jiachuan Video's controlling shareholder is planning a change in control, resulting in a temporary stock suspension [32] Group 10 - Danhua Technology will change its stock name to Jinmei Technology starting August 7, 2025, due to a relocation of its registered office [33] - Morning Wind Technology's shareholder plans to reduce holdings by up to 1% of the company's shares [34] - Leshan Electric will adjust residential gas prices starting September 1, 2025, which is expected to increase gross profit by approximately 2.7 million yuan [35] Group 11 - SAIC Motor reported a total vehicle sales of 337,500 units in July 2025, a year-on-year increase of 34.22%, with significant growth in new energy vehicle sales [36] - LIGONG Navigation's shareholders plan to reduce holdings by up to 3% of the company's shares [37] - United Imaging's employee stock ownership platform plans to reduce holdings by up to 1.62% of the company's shares [38] Group 12 - Beiqi Blue Valley's subsidiary reported a 6.38% decline in sales in July 2025 [39] - Watson Bio's clinical research application for an mRNA vaccine has been accepted [40]